收入
成本
利润
| Item | Category | Value | YoY |
|---|---|---|---|
| Revenues | revenue | 3.52B | 8.07% |
| Loss from operations | profit | 79.70M | -97.23% |
| Gross profit | profit | 1.16B | -0.34% |
| Cost of product and service sold | cost | 2.36B | 12.74% |
| Total operating expenses | cost | 1.24B | -69.41% |
| Selling, general and administrative expense | cost | 928.80M | -2.04% |
| Research and development expense | cost | 248.60M | 11.98% |
| Litigation settlements and other contingencies, net | revenue | 53.50M | -27.21% |
| Acquired ipr&d | cost | 6.00M | -40.00% |
| Segment | Value | YoY |
|---|---|---|
| Developed Markets | 2.03B | 6.71% |
| Greater China | 680.10M | 22.43% |
| Emerging Markets | 537.40M | 2.73% |
| Japan, Australia and New Zealand | 273.50M | -1.30% |
| Segment | Value | YoY |
|---|---|---|
| Brands | 2.33B | 10.18% |
| Generics | 1.18B | 4.52% |
| Lipitor ® | 462.00M | 19.07% |
| Norvasc ® | 210.00M | 21.88% |
| Lyrica ® | 120.60M | 7.10% |
| EpiPen® Auto-Injectors | 101.10M | 4.55% |
| Creon ® | 97.40M | 18.20% |
| Viagra ® | 95.00M | -3.55% |
| Zoloft ® | 72.60M | 20.60% |
| Celebrex ® | 67.10M | 5.84% |
| Yupelri ® | 62.50M | 7.20% |
| Effexor ® | 62.00M | 4.55% |
| Xalabrands | 39.20M | 5.66% |
| Dymista ® | 37.30M | -12.85% |
| Xanax ® | 34.80M | 7.74% |
| Amitiza ® | 34.00M | 2.10% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Inventories | assets | 3.93B | |
| Accounts receivable, net | assets | 3.08B | |
| Prepaid expenses and other current assets | assets | 2.11B | |
| Cash and cash equivalents | assets | 1.80B | |
| Total current assets | assets | 10.92B | |
| Intangible assets, net | assets | 14.48B | |
| Goodwill | assets | 6.69B | |
| Property, plant and equipment, net | assets | 2.53B | |
| Deferred income tax assets, net | assets | 1.11B | |
| Other assets | assets | 1.11B | |
| Total assets | assets | 36.83B | |
| Total liabilities | liabilities | 22.18B | |
| Less: treasury stock — at cost | assets | 1.01B | |
| Total equity | liabilities | 14.66B | |
| Long-term debt | liabilities | 12.41B | |
| Total current liabilities | liabilities | 6.81B | |
| Other long-term obligations | liabilities | 2.08B | |
| Deferred income tax liabilities, net | liabilities | 870.60M | |
| Accumulated other comprehensive income (loss), net of tax | liabilities | 2.80B | |
| Retained earnings (accumulated deficit) | liabilities | 211.90M | |
| Total viatris inc. equity, before treasury stock | liabilities | 15.66B | |
| Other current liabilities | liabilities | 3.13B | |
| Current portion of long-term debt and other long-term obligations | liabilities | 1.93B | |
| Accounts payable | liabilities | 1.75B | |
| Aggregate | liabilities | 18.68B | |
| Additional paid in capital | liabilities | 18.66B | |
| Common stock, value, issued | liabilities | 12.60M |
| Item | Value |
|---|---|
| Depreciation, depletion and amortization | 676.10M |
| Other noncash income (expense) | 182.30M |
| Net earnings (loss) attributable to viatris inc. common shareholders | 176.40M |
| Change in noncash litigation settlements, net | 58.00M |
| Share-based compensation expense | 48.20M |
| Accounts payable | 32.70M |
| Gain (loss) on disposition of business | 13.90M |
| Payments to acquire in process research and development, other | 6.00M |
| Increase (decrease) in other operating assets and liabilities, net | -22.90M |
| Deferred income tax benefit | -69.70M |
| Increase (decrease) in inventories | -123.00M |
| Increase (decrease) in accounts receivable | -126.30M |
| Increase (decrease) in income taxes payable | -463.40M |
| Item | Value |
|---|---|
| Proceeds from the sale of investments | 400.00M |
| Proceeds from the sale of marketable securities | 7.50M |
| Proceeds from the sale of property, plant and equipment | 1.60M |
| Purchases of ipr&d | -2.30M |
| Payments to acquire marketable securities | -7.50M |
| Payments to acquire property, plant, and equipment | -39.90M |
| Payment for (proceeds from) other investing activity | -82.00M |
| Item | Value |
|---|---|
| Issuance of common stock | 500000 |
| Other items, net | -300000 |
| Payments of merger related costs, financing activities | -7.90M |
| Payment, tax withholding, share-based payment arrangement | -56.50M |
| Payments to noncontrolling interests | -139.60M |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 1.35B |
| Cash and cash equivalents, end of period | 1.81B |
快速穿透 10-K/10-Q 复杂数据。通过利润表及资产负债表桑基图,与现金流量表瀑布图,一站式洞悉企业财务流向。
在左侧搜索公司并选择一份报告。
申请股票支持